Susanne Marschner

Susanne Marschner

Auto-generated profile, based on publicly available information

Susanne Marschner

Vitalant Research Institute Denver Colorado USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2014 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
SBS. Bakkour
S. Bakkour
DCD. M. Chafets
D. M. Chafets
LWL. Wen
L. Wen
PMP. F. van der Meer
P. F. van der Meer
JMJ. M. Mundt
J. M. Mundt
Tsung-Hsien LeeTsung-Hsien Lee
Tsung-Hsien Lee

9 April 2021 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
SYSusan Yonemura
Susan Yonemura
LHLindsay Hartson
Lindsay Hartson
TDTaru S Dutt
Taru S Dutt
MHMarcela I. Henao-Tamayo
Marcela I. Henao-Tamayo
Raymond P. GoodrichRaymond P. Goodrich
Raymond P. Goodrich
SMSusanne Marschner
Susanne Marschner
Background and objectives Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID‐19), while other treatments are developed. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is not transmissible by transfusion, but bloodborne pathogens remain a risk in regions with high endemic prevalence of disease. Pathogen reduction can mitigate this risk; thus, the objective of this study was to evaluate the effect of riboflavin and ultraviolet light (R + UV) pathogen reduction technology on the functional properties of COVID‐19 CP (CCP). Materials and methods COVID‐19 convalescent plasma units (n = 6) from recovered COVID‐19 research donors were treated with R + UV. Pre‐ and post‐treatment samples were tested for coagulation factor and immunoglobulin retention. Antibody binding to spike protein receptor‐binding domain (RBD), S1 and S2 epitopes of SARS‐CoV‐2 was assessed by ELISA. Neutralizing antibody (nAb) function was assessed by pseudovirus reporter viral particle neutralization (RVPN) assay and plaque reduction neutralization test (PRNT). Results Mean retention of coagulation factors was ≥70%, while retention of immunoglobulins was 100%. Starting nAb titres were low, but PRNT50 titres did not differ between pre‐ and post‐treatment samples. No statistically significant differences were detected in levels of IgG (P ≥ 0·3665) and IgM (P ≥ 0·1208) antibodies to RBD, S1 and S2 proteins before and after treatment. Conclusion R + UV PRT effects on coagulation factors were similar to previous reports, but no significant effects were observed on immunoglobulin concentration and antibody function. SARS‐CoV‐2 nAb function in CCP is conserved following R + UV PRT treatment.

19 June 2014 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
GLGwynn Long
Gwynn Long
EWEdmund Waller
Edmund Waller
SGSteven Gregurek
Steven Gregurek
GTGuido Tricot
Guido Tricot
SMSusanne Marschner
Susanne Marschner
JBJerry Bill
Jerry Bill

6 March 2026 in Transfusion
Verified
Journal Article
Closed access
SMSusanne Marschner
Susanne Marschner
DLDeborah Lee
Deborah Lee
NRNeeta Rugg
Neeta Rugg
BBBethany Brown
Bethany Brown
SNShawnagay Nestheide
Shawnagay Nestheide
JCJose A. Cancelas
Jose A. Cancelas

24 May 2026 in Vox Sanguinis
Verified
Journal Article
Closed access
BBBethany L. Brown
Bethany L. Brown
SMSamatha E. Mack
Samatha E. Mack
EMEmily Mason
Emily Mason
MWMichael Wellington
Michael Wellington
NRNeeta Rugg
Neeta Rugg
CACaroline Alquist
Caroline Alquist

23 June 2026 in Vox Sanguinis
Verified
Journal Article
Closed access
SMSusanne Marschner
Susanne Marschner
CACaroline R. Alquist
Caroline R. Alquist
BBBethany Brown
Bethany Brown
JRJoseph D. Rice
Joseph D. Rice
CGChristina Gloor
Christina Gloor
SMSamantha E. Mack
Samantha E. Mack